Kineta, Inc. (KANT)KANT

Upturn Advisory Summary

Analysis of Past Performance​

Type: Stock	Upturn Star Rating​	Today’s Advisory: PASS
Historic Profit: -89.05%	Upturn Advisory Performance 1	Avg. Invested days: 22
Profits based on simulation	Stock Returns Performance 1	Last Close 11/18/2024

Type: Stock	Today’s Advisory: PASS
Historic Profit: -89.05%	Avg. Invested days: 22
Upturn Star Rating​	Stock Returns Performance 1
Profits based on simulation Last Close 11/18/2024	Upturn Advisory Performance 1

Key Highlights

Earnings Date

Valuation

Analyst Ratings

About Kineta, Inc.

Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.